Jung H R, Turner S M, Neese R A, Young S G, Hellerstein M K
Department of Nutritional Sciences, University of California, Berkeley, CA94720-3104, USA.
Biochem J. 1999 Oct 15;343 Pt 2(Pt 2):473-8.
A mouse model of chylomicron deficiency was recently developed; these mice express a human apolipoprotein (apo) B transgene in the liver but do not synthesize any apoB in the intestine. Despite severe intestinal fat malabsorption, the mice maintain normal concentrations of plasma lipids and liver-derived apoB 100-containing lipoproteins. We investigated the metabolic mechanisms by which plasma lipid levels are kept normal. De novo lipogenesis (DNL) and cholesterogenesis were measured by mass isotopomer distribution analysis (MIDA). Plasma non-esterified fatty acid (NEFA) fluxes and hepatic re-esterification of labelled plasma NEFA were also measured. Hepatic and plasma triacylglycerol (TG) concentrations and plasma NEFA fluxes were not different between chylomicron-deficient mice and controls. The contribution from DNL to the hepatic TG pool was only modestly higher in chylomicron-deficient mice [12+/-2.1% (n=7) compared with 3.7+/-1.0% (n=9); means+/-S.E.M.], whereas cholesterogenesis was markedly elevated. The fractional contribution from plasma NEFA to hepatic TG was greatly elevated in the chylomicron-deficient animals (62% compared with 23%). Accordingly, 73% of hepatic TG was neither from DNL nor from plasma NEFA in controls, presumably reflecting prior contribution from chylomicron remnants, compared with only 26% in the chylomicron-deficient group. The long-term contribution from DNL to adipose fat stores reached approximately the same steady-state values (approximately 30%) in the two groups. Body fat accumulation was much lower in chylomicron-deficient animals; thus, whole-body absolute DNL was significantly lower. We conclude that plasma and hepatic TG pools and hepatic secretion of apoB-containing particles are maintained at normal levels in chylomicron-deficient mice, not by de novo fatty acid synthesis, but by more avid re-esterification of plasma NEFA, replacing the normally predominant contribution from chylomicrons, and that some dietary fat can be absorbed by apoB-independent mechanisms.
最近建立了一种乳糜微粒缺乏的小鼠模型;这些小鼠在肝脏中表达人载脂蛋白(apo)B转基因,但在肠道中不合成任何apoB。尽管存在严重的肠道脂肪吸收不良,但这些小鼠的血浆脂质和肝脏来源的含apoB 100的脂蛋白浓度仍保持正常。我们研究了血浆脂质水平保持正常的代谢机制。通过质量同位素异构体分布分析(MIDA)测量从头脂肪生成(DNL)和胆固醇生成。还测量了血浆非酯化脂肪酸(NEFA)通量和标记血浆NEFA的肝脏再酯化。乳糜微粒缺乏小鼠和对照组之间的肝脏和血浆三酰甘油(TG)浓度以及血浆NEFA通量没有差异。DNL对肝脏TG池的贡献在乳糜微粒缺乏小鼠中仅略高[12±2.1%(n = 7),而对照组为3.7±1.0%(n = 9);均值±标准误],而胆固醇生成明显升高。在乳糜微粒缺乏的动物中,血浆NEFA对肝脏TG的分数贡献大大升高(62%,而对照组为23%)。因此,对照组中73%的肝脏TG既不是来自DNL也不是来自血浆NEFA,这可能反映了乳糜微粒残粒的先前贡献,而在乳糜微粒缺乏组中仅为26%。两组中DNL对脂肪储存的长期贡献达到大致相同的稳态值(约30%)。乳糜微粒缺乏的动物体内脂肪积累要低得多;因此,全身绝对DNL明显较低。我们得出结论,在乳糜微粒缺乏的小鼠中,血浆和肝脏TG池以及含apoB颗粒的肝脏分泌维持在正常水平,不是通过从头脂肪酸合成,而是通过更积极地将血浆NEFA再酯化,取代了通常由乳糜微粒占主导的贡献,并且一些膳食脂肪可以通过不依赖apoB的机制被吸收。